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Prostate  cancer  remains  one  of the  leading  causes  of  cancer  death  in  men  around  the  world,  regardless
of  intense  research  and  development  of novel  therapies  in  the  last  10 years.  One  of the  new  avenues
that  has  been  tested  – inhibition  of angiogenesis  – has  been  disappointing  so far  in  clinical  studies  in
spite of strong  evidence  that  determinants  of  angiogenesis  (e.g.  vascular  endothelial  growth  factor)  are
strongly  associated  with  disease  progression.  One  of  the  reasons  for  these  outcomes  may  be  our  poorrostate cancer
ngiogenesis
lternative splicing
ovel therapeutics
understanding  of  the  biology  of  angiogenesis  in prostate  cancer  (and  probably  other  cancers  as  well)
resulting  in  inhibition  of both  detrimental  and  favourable  molecules.  We  discuss  here novel  targeted
and  more  speciﬁc  approaches  to inhibit  angiogenesis  in  prostate  cancer  as well  as  a completely  new
therapeutic  modality  to do  this  – modulation  of  alternative  splicing  –  that  may  be applicable  to  other
molecules/biological  processes  as well.
© 2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
In the last 15 years, there has been an increase in the use of
rugs that target angiogenesis in cancers. The most well-known
nti-angiogenic drug is Bevacizumab (Avastin), a humanized mon-
clonal antibody against vascular endothelial growth factor—A
VEGF-A) that is approved to be used in various cancers like
olon cancer, non-small cell lung cancer or kidney cancer [1,2].
owever, following the initial excitement regarding the use of
nti-angiogenics, they have not proven to induce a robust antitu-
oural treatment, with many clinical studies showing a modest
rogression-free survival and overall survival [3]. Additionally,
ide effects of such treatments may  be quite important [1]. While
here may  be several explanations for this situation, it is more and
ore clear that we do not understand enough the vascular biology
f tumours as well as many functional aspects of the molecules
nvolved, therefore missing the chance to design more targeted
reatments. This article discusses the current state of using anti-
ngiogenics in prostate cancer and our own work in ﬁnding a novel
ngle from which this problem may  be solved.
∗ Corresponding author at: School of Physiology, Pharmacology and Neuro-
ciences, Faculty of Biomedical Sciences, University of Bristol, Dorothy Hodgkin
uilding, Bristol BS1 3NY, UK.
E-mail address: sebastian.oltean@bristol.ac.uk (S. Oltean).
ttp://dx.doi.org/10.1016/j.phrs.2016.03.013
043-6618/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
2. Is there a rationale for developing anti-angiogenics in
prostate cancer?
2.1. Prostate cancer
Prostate cancer (PCa) is the most commonly diagnosed cancer
in men  in the Western world. Given its incidence, PCa is one of the
most considerable burdens on health systems around the world
and accounts for a considerable number of death by cancer in men.
The latest analysis of cancer statistics shows that in USA ∼27,000
patients died of PCa in 2015 [4]. The mainstay of PCa therapy, aside
from surgical intervention, is formed by a combination of anti-
androgens, chemotherapy and radiation therapy. However, despite
adequate treatment, a signiﬁcant proportion of men  progress to
the metastatic castration-resistant form. It is therefore established
that new avenues need to be found to be able to tackle this dis-
ease effectively. Indeed, in the last years several novel treatments
involving immunomodulators, vaccines, epigenetic modiﬁers or
bone-speciﬁc agents have been developed [5–7].
2.2. Evidence for the importance of angiogenesis in PCa
progressionInduction of angiogenesis, the development of new vessels from
existing ones, has long been recognized as an essential requirement
for tumours to grow above a certain size and is therefore established
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pig. 1. Basic mechanisms of splicing regulation. Positions of 5′ and 3′ splice sites, br
nd  silencers respectively. ISE and ISS: intron splicing enhancers and silencers, resp
election of a neighbouring splice site while binding to an ISI inhibits it.
s one of the hallmarks of cancer [8]. However, since angiogenesis
hould be more important in highly-vascularized cancers and not
low-growing like PCa it is essential to understand whether PCa
rogression is dependant on angiogenesis. In favour of this, several
reclinical and clinical studies have shown a strong association of
ngiogenic factors with PCa. For example, VEGF, a main determi-
ant of angiogenesis, was  found to be increased in plasma and urine
f patients with advanced PCa, whereas the microvessel density
as strongly associated with Gleason score and metastasis [9–11].
.3. Clinical trials using anti-angiogenics in PCa
Despite the above-mentioned evidence for the importance of
ngiogenesis in PCa, trials with different anti-angiogenic inhibitors
ombined with the main treatment for advanced PCa (Docetaxel
nd Prednisone) have failed to this date to show an improvement in
verall survival [12]. There are several possible explanations for the
ailure of these trials, including hetereogeneity in patient stages and
election, treatment-related toxicities or activation of resistance
echanism through induction of pro-angiogenic factors [12,13]. A
ecent phase II trial concludes that combination of anti-angiogenics
bevacizumab and lenalidomide—though arguably lenalidomide is
ig. 2. Common models of AS. (A) Cassette exon. (B) Mutually exclusive exon. (C) Alterna
romoter. (G) Alternative poly(A) site.oint (A) and polypyrimidine tract are shown. ESE and ESS: exon splicing enhancers
ly. Example of splicing regulation: binding of a splice factor (SF) to an ESE induces
not a “pure” anti-angiogenic) is able to circumvent the toxicity and
may  have clinical beneﬁt [14]. Despite the insufﬁcient data for the
effectiveness of anti-angiogenic treatment in PCa, the above men-
tioned studies suggest that further research is required to establish
the exact mechanism of regulation of angiogenesis in tumours.
Are we inhibiting the right molecules? There is certainly room for
improvement.
3. Alternative splicing and novel therapeutics
3.1. Alternative splicing as an important post-transcriptional
regulation level
Splicing is the removal of introns from the pre-mRNA and join-
ing of exons to form the mature RNA. The splicing reaction is
catalyzed by the spliceosome, a macromolecular ribonucleoprotein
complex that assembles at splice sites (exon-intron junctions) and
removes introns through two  transesteriﬁcation reactions. Beside
splice sites (that have loose consensus sequences) the reactive sites
in a basic splicing unit include a branch point involved in the trans-
tive 5′ splice site. (D) Alternative 3′ splice site. (E) Intron retention. (F) Alternative
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iig. 3. Regulation of alternative splicing by signalling. (A) In unstimulated cells, SR
GF-receptor) stimulates kinases such as SRPK1, which in turn phosphorylate SR p
,  denotes phosphorylated state.
steriﬁcation reaction and a polypirimidine tract that binds crucial
plice factors (Fig. 1).
Alternative splicing (AS), the re-arrangement of exons, introns
r parts of exons and introns in various combinations to result in
ultiple mature transcripts from the same pre-mRNA, has been
escribed more than 40 years ago. There are several modes of AS
ith the main categories being: A) cassette exon – when an exon is
ither included or excluded in the mature transcript; B) mutually
xclusive exons – a mature transcript contains either one of two
xons but not both at the same time; C) and D) 5′ and 3′ alternative
plice sites – resulting in inclusion/exclusion of parts of exons; E)
ntron retention – when an intron is not excised and appears in the
ig. 4. Different mechanisms for potential spliced-based therapeutics. (A) Splice-switch
nhibit  activation of splice factors or (ii–iv) can modulate selection of splice sites.ins reside in the cytoplasm. (B) Activation of trasmembrane receptors (for example
s; they move into the nucleus to change the splicing pattern of various transcripts.
mature RNA (Fig. 2). Combinations with other gene regulations lev-
els may  result in even more transcript diversity, e.g. F) alternative
promoters or G) alternative poly(A) sites (Fig. 2)
What has only recently been established though, is how exten-
sive AS is. Indeed deep sequencing studies have conclusively show
that more than 95% of human genes are alternatively spliced [15,16]
providing a rationale for the existence of the estimated hundreds
of thousands of proteins from only ∼22,000 genes [17]. The extent
of AS places this process as a major player in gene regulation and
therefore determinant of cell function.
ing oligonucleotides. (B) Small molecule splicing modulators (red shape) can (i)
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.2. Regulation of AS
The decision to include or exclude a particular exon is based on
he interaction between cis-  and trans-acting trans-acting elements.
is elements consist of regions were splice factors bind. Depending
n the position and outcome of exon regulation they are divided in
xonic and intronic splicing silencers (ESS and ISS) or exonic and
ntronic splicing enhancers (ESE and ISE) (Fig. 1).
Trans-acting regulatory molecules are splice factors – two  of
he most important classes that are ubiquitously expressed are
erine-arginine (SR) proteins and heterogenous ribonucleoproteins
hnRNPs). A fair number of RNA-binding proteins have also been
escribed to be splice factors and are not included in either of these
wo classes. Many of these have tissue-speciﬁc distribution or reg-
late deﬁned processes like brain functions or muscle development
 e.g. Nova, Rbm24 [18,19] or the epithelial state of a cell – ESRP1
nd 2 [20,21].
Splice factors, similar to transcription factors, are integrated in
ignalling pathways, such as those regulated by transmembrane
eceptor activation. Binding of a signalling molecule to its receptor,
hosphorylates and thus activates a SF, which then translocates
nto the nucleus to regulate processing of its target RNAs (Fig. 3).
.3. AS and cancerGiven the extent of AS, it is not surprising that there are
housands of isoforms speciﬁcally associated with disease progres-
ion, including oncogenesis [22]. Splicing variants are described in
lmost every class of molecules, including growth factors, tyro-erminal exon results in formation of anti-angiogenic “b” isoforms.
sine receptors, tumour suppressors and oncogenes. Many times
the splicing isoforms have opposing functions e.g pro- or anti-
angiogenic, pro- or anti-apoptotic [see recent reviews [22,23]]. Two
recent reports in Nature highlight the close connection between
Myc, one of the most important oncogenes, and the splicing
machinery [24,25]. It is therefore not surprising that AS manipu-
lation has recently emerged as a novel area in which therapeutic
intervention may  be designed, with the general idea being to try
and switch isoforms that are characteristic to cancer and assist in
its progression, to their normal counterparts [26].
3.4. Modulation of splicing for therapeutic beneﬁt
One of the greatest advances in the development of splicing
therapeutics so far is the concept of splicing-switching oligonu-
cleotides (SSOs) (Fig. 4A). These are complementary sequences
designed to bind exon-intron junctions or intronic/exonic regula-
tory elements and thus affect splicing outcomes.
Another concept, that of small molecules splicing modulators
(smSM) that can be used in therapeutics, has also gained the inter-
est of the splicing ﬁeld recently. Theoretically smSMs  may be
designed at several levels that can affect splicing outcomes (Fig. 4B),
such as inhibitors of kinases that are speciﬁc regulators of splice
factors (like the example related to SRPK1 from our own work
described below), modulators of protein–protein or protein-RNA
interactions at splice sites or modulators of RNA tertiary structure
at splice sites.
For a long time there has been reluctance on whether splic-
ing therapeutics can be speciﬁc enough, given the large number
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f splice sites and their loose consensus sequences. However, the
nique characteristics of a splice site are given by many factors
ncluding the secondary and tertiary RNA structure, interactions of
plice factors bound to those sites either with each other or with
NA. Recently, two studies have screened large chemical libraries
or modulators of SMN  splicing in a quest to develop novel ther-
peutics for spinal muscular atrophy [27,28]. Remarkably, deep
equencing showed that their lead compounds are highly speciﬁc
affect less than 10 additional splice sites). Speciﬁcally, one of the
eports describes that the mechanism of action of one of the com-
ounds is through disruption of the interaction between a splice
actor and RNA [28].
. SRPK1 as a novel therapeutic target in PCa
Serine-arginine protein kinase 1 (SRPK1) is a kinase that phos-
horylates SR- proteins and modulates their activity. It has been
hown to be upregulated in numerous cancers—breast, colon
ndpancreatic carcinomas [29], hepatocellular carcinoma [30],
sophageal squamous carcinomas [31], ovarian [32] and lung can-
ers [33] or glioma [34]. We  have recently shown that it is strongly
pregulated in PCa tissues and correlates with disease stage and
nvasion [35].
We  have reported previously [36] that SRPK1 is a key regula-
or of the balance between two splice isoforms − VEGF165a, the
anonical one that is proangiogenic and VEGF165b, resulting from
n alternative 3′ splice site in the terminal exon (see Fig. 5) that
as been shown in numerous studies to be anti-angiogenic [37,38].
his is accomplished through phosphorylation of the splice factor
RSF1. Moreover, knockdown of SRPK1 in a colon carcinoma cell
ine decreased tumour growth and microvessel density [36].
Based on this data we enquired whether this is also true in
Ca. Knockdown of SRPK1 switched VEGF splicing towards the
ntiangiogenic isoform in PC3 cells line and decreased tumour
rowth in xenografts as well as microvessel density in tumours
39]. Although SRPK1 has been shown to regulate other tumorigenic
unctions [40], we have not found any evidence that SRPK1 changes
roliferation, migration or invasion in PC3 cells. Moreover, in a res-
ue experiment, we have shown that if VEGF is expressed from
 construct that cannot be spliced, it rescues the tumour growth
henotype seen in SRPK1 knockdown cells, therefore suggesting
hat the effect we see in PC3 is mainly due to affecting angiogen-
sis through a switch in VEGF splicing. Finally, in a therapeutic
roof-of-principle experiment we have shown that intraperitoneal
dministration of a speciﬁc SRPK1 inhibitor (SPHINX) is able to
educe tumour growth in an orthotopic mouse model of PCa.
Our human data on a cohort of 110 patients with PCa showed
hat SRPK1 expression is strongly associated with disease stage and
nvasion but not with Gleason score. This supports our ﬁndings in
he pre-clinical studies that SRPK1 is a determinant of angiogenesis
n PCa, as such it would not affect cell morphology (and therefore
leason score) but contribute to its aggressiveness by stimulating
ngiogenesis.
. Concluding remarks and future directions
The failure of clinical trials using antiangiogenics in PCa so far,
espite strong evidence that angiogenesis is crucial for PCa progres-
ion, has pointed out that we need to understand better the biology
f vessels and angiogenesis in tumours, the various functions of
ngiogenic regulators and design better targeted treatments. Once
uch example might be the inhibition of SRPK1, which is highly
xpressed in PCa and drives expression of the pro-angiogenic VEGF
plice isoforms, and not the beneﬁcial anti-angiogenic ones, which
re also inhibited by the current anti-VEGF therapies.
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